Classifications: antihypertensive agent; angiotensin-converting enzyme (ace) inhibitor; Therapeutic: antihypertensive agent; ace inhibitor
Pregnancy Category: D second and third trimester; C first trimester
5 mg, 10 mg, 20 mg, 40 mg tablets
Lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE) and thus by decreasing angiotensin
II (a potent vasoconstrictor) and aldosterone secretion.
Achieves an antihypertensive effect by suppression of the renin-angiotensin-aldosterone system.
Treatment of mild to moderate hypertension.
CHF, reno-protective agent.
Hypersensitivity to benazepril or another ACE inhibitor; pregnancy (category C first trimester and category D second and
third trimester), lactation, or in children <6 y or with a GFR <30 mL/h.
Renal impairment, renal-artery stenosis; patients with hypovolemia, receiving diuretics, undergoing dialysis; patients in
whom excessive hypotension would present a hazard (e.g., cerebrovascular insufficiency); CHF; hepatic impairment; diabetes
Route & Dosage
Adult: PO 1040 mg/d in 12 divided doses
- Consult physician about initial dose if patient is also receiving diuretics. Typically an initial dose of 5 mg is used to
minimize the risk of hypotension.
- Store at room temperature, but not above 30° C (86° F).
Adverse Effects (≥1%)CV:
Hypotension. CNS: Headache,
, weakness. Endocrine:
Hyperkalemia (at higher doses). GI:
Nausea, diarrhea or constipation
Azotemia, oliguria, renal failure in patients with CHF. Respiratory:
Cough, rhinitis, bronchitis
Diagnostic Test Interference
Elevations in serum bilirubin have been observed after benazepril administration. Benazepril inhibits aldosterone secretion, which causes an increase in serum potassium.
Interactions Drug: potassium-sparing diuretics
may increase the risk of hyperkalemia. Benazepril may increase lithium
levels, resulting in lithium
Readily from GI tract; 37% reaches the systemic circulation. Peak:
26 h. Duration:
2024 h. Distribution:
Small amounts cross the blood-brain barrier; crosses placenta; small amount excreted in breast milk. Metabolism:
In liver to active metabolite, benazeprilat. Elimination:
Benazeprilat is primarily excreted in urine. Half-Life:
Benazepril 0.6 h; benazeprilat 22 h.
Assessment & Drug Effects
- Assess for hypotension, especially in patients who may be volume depleted (e.g., prolonged diuretic therapy, recent vomiting
or diarrhea, salt restriction) or who have CHF.
- Lab tests: Monitor serum potassium levels for hyperkalemia (see Appendix F).
Patient & Family Education
- Do not use salt substitutes unless recommended by physician.
- Report swelling of face, eyes, lips, or tongue or difficulty breathing immediately to physician.